18,635 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Paloma Partners Management Co

Paloma Partners Management Co bought a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 18,635 shares of the biotechnology company's stock, valued at approximately $484,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Farallon Capital Management LLC lifted its stake in shares of Exelixis by 1.6% in the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company's stock worth $608,993,000 after buying an additional 424,000 shares in the last quarter. Renaissance Technologies LLC lifted its position in Exelixis by 0.4% during the second quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company's stock valued at $340,714,000 after purchasing an additional 61,350 shares during the period. LSV Asset Management lifted its position in Exelixis by 107.7% during the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company's stock valued at $129,511,000 after purchasing an additional 2,989,021 shares during the period. Dimensional Fund Advisors LP lifted its position in Exelixis by 7.3% during the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company's stock valued at $115,434,000 after purchasing an additional 349,837 shares during the period. Finally, AQR Capital Management LLC lifted its position in Exelixis by 12.7% during the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company's stock valued at $73,425,000 after purchasing an additional 370,199 shares during the period. Institutional investors own 85.27% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on EXEL. Wells Fargo & Company upped their target price on shares of Exelixis from $32.00 to $36.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. JMP Securities restated a "market outperform" rating and set a $29.00 target price on shares of Exelixis in a research report on Friday, October 11th. Morgan Stanley upped their target price on shares of Exelixis from $26.00 to $28.00 and gave the stock an "equal weight" rating in a research report on Friday, October 11th. Royal Bank of Canada reiterated an "outperform" rating and set a $34.00 price objective on shares of Exelixis in a research report on Wednesday, October 30th. Finally, UBS Group began coverage on shares of Exelixis in a research report on Thursday, September 19th. They set a "neutral" rating and a $30.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Exelixis has a consensus rating of "Moderate Buy" and an average target price of $31.44.

Exelixis Price Performance

NASDAQ EXEL traded up $0.27 during trading on Thursday, reaching $36.04. 1,646,313 shares of the company's stock traded hands, compared to its average volume of 2,066,896. The firm has a market cap of $10.29 billion, a price-to-earnings ratio of 23.10, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52. The company's 50 day simple moving average is $31.38 and its two-hundred day simple moving average is $26.42. Exelixis, Inc. has a 12-month low of $19.20 and a 12-month high of $36.97.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating analysts' consensus estimates of $0.36 by $0.04. The business had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company's revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.10 EPS. Research analysts expect that Exelixis, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Exelixis

In other news, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total value of $352,700.00. Following the transaction, the executive vice president now owns 278,665 shares of the company's stock, valued at $9,828,514.55. The trade was a 3.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at approximately $17,823,783.53. The trade was a 10.99 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 339,736 shares of company stock valued at $11,508,610. Company insiders own 2.85% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.